Verrica Pharmaceuticals Inc (NASDAQ: VRCA) on Tuesday, plunged -2.50% from the previous trading day, before settling in for the closing price of $0.70. Within the past 52 weeks, VRCA’s price has moved between $0.61 and $11.41.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -13.60% annually for the last half of the decade. The company achieved an average annual earnings per share of -2.03%. With a float of $49.03 million, this company’s outstanding shares have now reached $90.56 million.
In an organization with 100 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 72.9%, operating margin of -815.5%, and the pretax margin is -922.81%.
Verrica Pharmaceuticals Inc (VRCA) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Verrica Pharmaceuticals Inc is 45.86%, while institutional ownership is 15.81%. The most recent insider transaction that took place on Aug 26 ’24, was worth 69,647. In this transaction CHIEF LEGAL OFFICER of this company sold 26,183 shares at a rate of $2.66, taking the stock ownership to the 115,303 shares. Before that another transaction happened on Aug 27 ’24, when Company’s CHIEF LEGAL OFFICER sold 9,530 for $2.46, making the entire transaction worth $23,444. This insider now owns 105,773 shares in total.
Verrica Pharmaceuticals Inc (VRCA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -2.03% per share during the next fiscal year.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Trading Performance Indicators
Verrica Pharmaceuticals Inc (VRCA) is currently performing well based on its current performance indicators. A quick ratio of 1.22 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.83, a number that is poised to hit -0.28 in the next quarter and is forecasted to reach -0.56 in one year’s time.
Technical Analysis of Verrica Pharmaceuticals Inc (VRCA)
Let’s dig in a bit further. During the last 5-days, its volume was 0.7 million. That was better than the volume of 0.5 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 27.99%. Additionally, its Average True Range was 0.11.
During the past 100 days, Verrica Pharmaceuticals Inc’s (VRCA) raw stochastic average was set at 1.44%, which indicates a significant decrease from 12.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.72% in the past 14 days, which was lower than the 161.99% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0883, while its 200-day Moving Average is $4.5312. However, in the short run, Verrica Pharmaceuticals Inc’s stock first resistance to watch stands at $0.7226. Second resistance stands at $0.7594. The third major resistance level sits at $0.7854. If the price goes on to break the first support level at $0.6598, it is likely to go to the next support level at $0.6338. Assuming the price breaks the second support level, the third support level stands at $0.5970.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Key Stats
Market capitalization of the company is 60.57 million based on 45,601K outstanding shares. Right now, sales total 5,120 K and income totals -67,000 K. The company made 5,180 K in profit during its latest quarter, and -17,190 K in sales during its previous quarter.
